Literature DB >> 3361121

Renal effects of acute and long-term treatment with felodipine in essential hypertension.

U L Hulthén1, P L Katzman.   

Abstract

Enhanced renal vasoconstriction and renal tubular sodium reabsorption mediated by noradrenaline and angiotensin II (Ang II) have been implicated in the pathogenesis of essential hypertension. Since these effects seem to be calcium-dependent, renal haemodynamic and tubular function were studied following acute and long-term treatment with the calcium antagonist felodipine in 10 patients with essential hypertension. After acute felodipine administration mean blood pressure (MBP) decreased (from 111 to 95 mmHg; P less than 0.01), renal blood flow (RBF), estimated from hippurate clearance, increased (from 1030 to 1175 ml/min; P less than 0.01) and glomerular filtration rate (GFR) was unchanged (109 versus 112 ml/min). Fractional excretion (FE) of sodium, potassium, calcium, magnesium, chloride, bicarbonate and urate increased for 12 h. Following long-term felodipine treatment, mean blood pressure was reduced (97 mmHg; P less than 0.01) and RBF and GFR were unchanged (1032 and 114 ml/min, respectively). Fractional excretion of urate and calcium was increased for 24 h (from 5.9 to 6.9%; P less than 0.05 and from 1.1 to 1.3%; P less than 0.05, respectively). Serum urate decreased (from 377 to 347 mumol/l; P less than 0.01) whereas serum calcium was unchanged. Fractional excretion of sodium, potassium and chloride was increased between 3 and 6 h after felodipine. The renal haemodynamic findings after acute felodipine administration are indicative of a direct renal vasodilator action of felodipine which augments the autoregulatory renal vasodilation to produce an overall increase in RBF. Since GFR was unchanged, the increased renal excretion of electrolytes and urate reflects an action at the tubular level. Following long-term felodipine administration autoregulatory adjustment of RBF predominated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3361121     DOI: 10.1097/00004872-198803000-00008

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

1.  Felodipine in combination with a beta-adrenoceptor blocker as an effective substitute for triple therapy in severe hypertension. The Australian Felodipine Multicentre Study Group.

Authors:  D B Frewin; P Aldons; L L Wilson; E F O'Sullivan; R N Wyndham; J Karrasch; J Agar; B B Singh; B Jackson; P F Atkins
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Effects of calcium antagonists on the hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

3.  Effects of felodipine on atrial natriuretic peptide in hypertensive non-insulin dependent diabetes mellitus.

Authors:  R F Jeffrey; S Capewell; J Brown; A Collier; C Hajducka; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

4.  The acute haemodynamic and renal effects of oral felodipine and ramipril in healthy subjects.

Authors:  B Hasselgren; B Edgar; G Johnsson; O Rönn
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

6.  Felodipine in the treatment of patients with severe hypertension and impaired renal function.

Authors:  R Larsson; M K Lindsjö; B Danielsson; U Bengtsson; J H Hardlund; P A Sjöström; D Elmfeldt; L Moberg
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 7.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in older patients.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

8.  Natriuretic and diuretic effects of felodipine and hydrochlorothiazide after single and repeated doses.

Authors:  B Hasselgren; P Johansson
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 9.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

10.  Renal effects of nicardipine, a calcium antagonist, in hypertensive type 2 (non-insulin-dependent) diabetic patients with and without nephropathy.

Authors:  T Baba; T Tomiyama; S Murabayashi; K Takebe
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.